Lantern Pharma Inc (LTRN)

08:09 AM

Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2024 Earnings Call Transcript - Insider Monkey

08:09 AM

Mar 28, 2025

Lantern Pharma’s Earnings Call: AI Advances Amid Financial Challenges - TipRanks

Mar 28, 2025

Mar 28, 2025

Lantern Pharma Advances AI-Driven Oncology Pipeline - TipRanks

Mar 28, 2025

Mar 27, 2025

Lantern Pharma outlines 2025 clinical milestones and key updates on oncology trials - MSN

Mar 27, 2025

Mar 27, 2025

LANTERN PHARMA Earnings Results: $LTRN Reports Quarterly Earnings - Nasdaq

Mar 27, 2025

Mar 27, 2025

Earnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expenses - Investing.com India

Mar 27, 2025

Mar 27, 2025

Earnings call transcript: Lantern Pharma’s Q4 2024 results show increased R&D expenses By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

Lantern Pharma Inc Qtrly EPS $-0.54 - Marketscreener.com

Mar 27, 2025

Mar 27, 2025

Lantern Pharma Inc (LTRN) Reports Q4 EPS of -$0.51, Aligning wit - GuruFocus.com

Mar 27, 2025

Mar 27, 2025

Lantern Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025

Mar 27, 2025

Lantern Pharma Reports Q4 2024 Financial Results and AI Progress - TipRanks

Mar 27, 2025

Mar 27, 2025

Lantern Pharma Reports 86% Clinical Benefit Rate in Cancer Trial, Q4 Results | LTRN Stock News - StockTitan

Mar 27, 2025

Mar 26, 2025

Preview: Lantern Pharma's Earnings - Benzinga

Mar 26, 2025

Mar 25, 2025

Lantern Pharma Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView

Mar 25, 2025

Mar 20, 2025

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET - BioSpace

Mar 20, 2025

Mar 20, 2025

Lantern Pharma's AI Platform Breakthrough: Q4 Results and Clinical Trial Milestones Revealed - StockTitan

Mar 20, 2025

Mar 10, 2025

LTRN: M&A Illuminates GBM Value - Yahoo Finance

Mar 10, 2025

Mar 10, 2025

Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN) - Defense World

Mar 10, 2025

Mar 10, 2025

Lantern Pharma (LTRN) Expected to Announce Earnings on Monday - Defense World

Mar 10, 2025

Mar 07, 2025

Sanctuary Advisors LLC Purchases New Holdings in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World

Mar 07, 2025

Feb 20, 2025

Lantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction Tech - Insider Monkey

Feb 20, 2025

Feb 19, 2025

Lantern Pharma advances AI-driven drug development with patent - Investing.com India

Feb 19, 2025

Feb 19, 2025

Lantern Pharma advances AI-driven drug development with patent By Investing.com - Investing.com Nigeria

Feb 19, 2025

Feb 19, 2025

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates - Business Wire

Feb 19, 2025

Feb 04, 2025

Perigon Wealth Management LLC Decreases Stake in Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World

Feb 04, 2025

Jan 28, 2025

Lantern Pharma (NASDAQ:LTRN) Stock Price Down 15% – Here’s What Happened - Defense World

Jan 28, 2025

Jan 27, 2025

Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies - Yahoo Finance

Jan 27, 2025

Jan 27, 2025

Top 10 AI Stocks Dominating Wall Street - Insider Monkey

Jan 27, 2025

Jan 27, 2025

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer - BioSpace

Jan 27, 2025

Jan 26, 2025

Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire

Jan 26, 2025

Jan 21, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Jan 21, 2025

Jan 17, 2025

Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development - Insider Monkey

Jan 17, 2025

Jan 10, 2025

Lantern Pharma Extends CSO’s Employment Agreement - TipRanks

Jan 10, 2025

Jan 04, 2025

Lantern Pharma (NASDAQ:LTRN) Stock Price Up 13.3% – What’s Next? - Defense World

Jan 04, 2025

Jan 02, 2025

Oncology Drugs Fast-Tracked by the FDA in December 2024 - Oncology News Central

Jan 02, 2025

Dec 22, 2024

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Yahoo Finance

Dec 22, 2024

Dec 10, 2024

AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan - Insider Monkey

Dec 10, 2024

Dec 09, 2024

Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial - Yahoo Finance

Dec 09, 2024

Dec 09, 2024

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - Business Wire

Dec 09, 2024

Dec 07, 2024

Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer - Yahoo Finance

Dec 07, 2024

Dec 06, 2024

15 AI News Updates That Broke The Internet - Insider Monkey

Dec 06, 2024

Dec 03, 2024

LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan

Dec 03, 2024

Dec 03, 2024

Lantern Pharma Shares Rise After Fast-Track Designation for Cancer Treatment - Marketscreener.com

Dec 03, 2024

Dec 03, 2024

LP-184 gains FDA fast track for triple negative breast cancer - Investing.com

Dec 03, 2024

Dec 03, 2024

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) - Eagle-Tribune

Dec 03, 2024

Nov 26, 2024

Lantern Pharma's LP-184 Shows 6x Better GBM Treatment Efficacy in Latest Trial Data | LTRN Stock News - StockTitan

Nov 26, 2024

Nov 26, 2024

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - BioSpace

Nov 26, 2024